Aromatase Inhibitors in Human Lung Cancer Therapy
- 15 December 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 65 (24), 11287-11291
- https://doi.org/10.1158/0008-5472.can-05-2737
Abstract
Lung cancer is the most common cancer in the world. It is a highly lethal disease in women and men, and new treatments are urgently needed. Previous studies implicated a role of estrogens and estrogen receptors in lung cancer progression, and this steroidal growth-stimulatory pathway may be promoted by tumor expression and activity of aromatase, an estrogen synthase. We found expression of aromatase transcripts and protein in human non-small cell lung cancer (NSCLC) cells using reverse transcription-PCR and Western immunoblots, respectively. Aromatase staining by immunohistochemistry was detected in 86% of archival NSCLC tumor specimens from the clinic. Further, biological activity of aromatase was determined in NSCLC tumors using radiolabeled substrate assays as well as measure of estradiol product using ELISA. Significant activity of aromatase occurred in human NSCLC tumors, with enhanced levels in tumor cells compared with that in nearby normal cells. Lung tumor aromatase activity was inhibited by anastrozole, an aromatase inhibitor, and treatment of tumor cells in vitro with anastrozole led to significant suppression of tumor cell growth. Similarly, among ovariectomized nude mice with A549 lung tumor xenografts, administration of anastrozole by p.o. gavage for 21 days elicited pronounced inhibition of tumor growth in vivo. These findings show that aromatase is present and biologically active in human NSCLCs and that tumor growth can be down-regulated by specific inhibition of aromatase. This work may lead to development of new treatment options for patients afflicted with NSCLC.Keywords
This publication has 16 references indexed in Scilit:
- Estrogen Receptor α and β are Prognostic Factors in Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Estrogen and growth factor receptor interactions in human breast and non-small cell lung cancer cellsSteroids, 2005
- Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative EffectsCancer Research, 2005
- Lung Cancer in US WomenJAMA, 2004
- Regulation of Postnatal Lung Development and Homeostasis by Estrogen Receptor βMolecular and Cellular Biology, 2003
- Expression of estrogen receptors α and β in human lung tissue and cell linesLung Cancer, 2002
- Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor κBPublished by Elsevier BV ,2001
- Estrogen Acutely Stimulates Endothelial Nitric Oxide Synthase in H441 Human Airway Epithelial CellsAmerican Journal of Respiratory Cell and Molecular Biology, 1999
- The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cellsOncogene, 1997
- Re: Endocrine Factors and Adenocarcinoma of the Lung in WomenJNCI Journal of the National Cancer Institute, 1994